Pathomechanisms of the development of obesity in some endocrinopathies - An overview

Endokrynologia Polska

Volumn 64, Issue 2, 2013, Pages 150-155

  Pujanek, Małgorzata ^a   Bronisz, Agata ^a   Małecki, Piotr ^b   Junik, Roman ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Novo Nordisk Pharma Ltd   (Poland)

Author keywords

Adipokines; Endocrinopathies; Obesity

Indexed keywords

ADIPONECTIN; GHRELIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GROWTH HORMONE; INSULIN; LEPTIN; NEUROPEPTIDE Y; THYROTROPIN;

ADIPOSE TISSUE; ANDROGEN DEFICIENCY; AUTOIMMUNE THYROIDITIS; BLOOD BRAIN BARRIER; BODY FAT; BODY MASS; BODY TEMPERATURE; BROWN ADIPOSE TISSUE; CENTRAL NERVOUS SYSTEM; ENDOCRINE DISEASE; ENERGY EXPENDITURE; FEMALE INFERTILITY; FOOD INTAKE; GROWTH HORMONE DEFICIENCY; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HYPERANDROGENISM; HYPERCORTISOLISM; HYPERPHAGIA; HYPERPROLACTINEMIA; HYPOPHYSIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOPITUITARISM; HYPOTHYROIDISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; MORBID OBESITY; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; REVIEW; STOMACH MOTILITY; THYROID DISEASE; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOKINES; ADIPOSE TISSUE; ENDOCRINE GLANDS; ENDOCRINE SYSTEM DISEASES; GHRELIN; HOMEOSTASIS; HUMANS; OBESITY;

EID: 84878118144     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. WHO, 2011. Available from: http://www.who.int/mediacentre/factsheets/ fs311/ en/index1
2. Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest 2002; 25: 855-861. (Pubitemid 35446352)
3. Wiecek A, Kokot F, Chudek J et al. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002; 17: 191-195. (Pubitemid 34157125)
4. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-145. (Pubitemid 36733912)
5. Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol (Oxf). 2012 Jan 7. doi: 10.1111/j.1748-1716.2012.02409.x. [Epub ahead of print].
6. Gnacińska M, Małgorzewicz S, Guzek M et al. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol 2010; 61: 160-168.
7. Morton NM. Obesity and corticosteroids: 11b-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010; 316: 154-164.
8. Del Prete A, Iadevaia M, Loguercio C. The role of gut hormones in controlling the food intake. What is their role in emerging diseases? Endocrinol Nutr 2012; 59:197-206.
9. Greenwood HC, Bloom SR, Murphy KG. Peptides and their potential role in the treatment of diabetes and obesity. Rev Diabet Stud. 2011; 8: 355-68.
10. Zhang L, Bijker MS, Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacology & Therapeutics 2011; 131: 91-113.
11. Nguyena AD, Herzoga, H, Sainsbury A. Neuropeptide Y and peptide YY: important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes 2011; 18: 56-60.
12. Joost H-G (ed.). Appetite Control. Handbook of Experimental Pharmacology 209, Springer-Verlag Berlin Heidelberg 2012;
13. Kirchner H, Heppner KM, Tschöp MH. The Role of Ghrelin in the Control of Energy Balance 161-184
14. Ladenheim EE. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control. Curr Opin Endocrinol Diabetes Obes 2012; 19: 13-18.
15. Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans - potential application in the treatment of obesity. Peptides 2011; 32: 2290-2294.
16. Tucholski K, Otto-Buczkowska E. The role of leptin in the regulation of carbohydrate metabolism. Endokrynol Pol 2011; 62: 258-261.
17. Magnotti M, Futterweit W. Obesity and the polycystic ovary syndrome. Med Clin North Am. 2007; 91: 1151-1168, ix-x. (Pubitemid 47628858)
18. Considine RV, Sinha MK, Heiman M. et al. Serum immunoreactiveleptin concentrations in normal weight and obese humans. N Engl J Med. 1996; 334: 292-295. (Pubitemid 26033933)
19. Havel PJ, Kasim-Karakas S, Dubuc GR et al. Gender differences in plasma leptin concentrations. Nat Med 1996; 2: 949-950. (Pubitemid 26306822)
20. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol 2010; 316: 165-171.
21. Feldt-Rasmussen U. Thyroid and leptin. Thyroid 2007; 17: 413-419. (Pubitemid 46878844)
22. Boguszewski CL, Paz-Filho G, Velloso LA. Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynol Pol 2010; 61: 194-206.
23. Knudsen N, Laurberg P, Rasmussen LB et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90: 4019-4024. (Pubitemid 41058166)
24. Rotondi M, Magri F, Chiovato L. Thyroid and Obesity: Not a One-Way Interaction. J Clin Endocrinol Metab 2011; 96: 344-346.
25. Michalaki MA, Vagenakis AG, Leonardou AS et al.Thyroid function in humans with morbid obesity. Thyroid 2006; 16: 73-78. (Pubitemid 43348719)
26. Rotondi M, Leporati P, La Manna A et al.Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism? Eur J Endocrinol 2009; 160: 403-408.
27. Marzullo P, Minocci A, Tagliaferri MA et al. Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab 2010; 95: 3965-3972.
28. Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med 1984; 76: 963-970. (Pubitemid 14120399)
29. Asvold BO, Bjøro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab 2009; 94: 5023-5027.
30. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab 2010; 95: 3614-3617.
31. Diez JJ, Iglesias P. Relationship between thyrotropin and body mass index in euthyroid subjects. Exp Clin Endocrinol Diabetes 2011; 119: 144-150.
32. Tamer G, Mert M, Tamer I et al. Effects of thyroid autoimmunity on abdominal obesity and hyperlipidaemia. Endokrynol Pol 2011; 62: 421-428.
33. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6: 438-446.
34. Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749. (Pubitemid 38766360)
35. Weaver JU. Classical endocrine diseases causing obesity. Front Horm Res. 2008; 36: 212-228.
36. Pinkney JH, Goodrick SJ, Katz JR et al. Thyroid and sympathetic influences on plasma leptin in hypothyroidism and hyperthyroidism. Int J Obes Relat Metab Disord 2000; 24: S165-S166. (Pubitemid 30461986)
37. Menendez C, Baldelli R, Camiña JP et al. TSH stimulates leptin secretion by a direct effect on adipocytes. J Endocrinol 2003; 176: 7-12. (Pubitemid 36163561)
38. Santini F, Galli G, Maffei M et al. Acute exogenous TSH administration stimulates leptin secretion in vivo. Eur J Endocrinol 2010; 163: 63-67.
39. Oge A, Bayraktar F, Saygili F et al. TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. Endocr J 2005; 52: 213-217. (Pubitemid 40745709)
40. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 671-683. (Pubitemid 40424604)
41. Asunción M, Calvo RM, San Millán JL et al.A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438.
42. Vribkova J, Hainer V. Obesity and polycystic ovary syndrome. Obesity Facts 2009; 2: 26-35.
43. Ehrmann DA, Barnes RB, Rosenfield RL et al. Prevalence of impaired glucose tolerance and diabetes in woman with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146. (Pubitemid 29028311)
44. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
45. Norman RJ, Dewailly D, Legro RS et al.Polycystic ovary syndrome. Lancet 2007; 370: 685-697. (Pubitemid 47285318)
46. Moran LJ, Lombard CB, Lim S et al. Polycystic ovary syndrome and weight management. Womens Health (Lond Engl) 2010; 6: 271-283.
47. Futterweit W et al. An endocrine approach to obesity. In: Simopoulos AP, VanItallie TB, Gullo SP (eds.). Obesity: New Directions in Assessment and Management. New York: Charles Press 1994: 96-121.
48. Panidis D, Kourtis A, Farmakiotis D et al. Serum adioponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003; 18: 1790-1796. (Pubitemid 37107549)
49. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetics study. Hum Reprod 2006; 21: 2257-2265. (Pubitemid 44530598)
50. Glintborg D, Andresen M, Hagen C et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006; 155: 337-345. (Pubitemid 44269452)
51. Carmina E, Orio F, Palomba S et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 389-394. (Pubitemid 40439491)
52. Hauner H, Entenmann G, Wabitsch M et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 1989; 84: 1663-1670. (Pubitemid 19272257)
53. Rask E, Olsson T, Söderberg S et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421. (Pubitemid 32323037)
54. Rask E, Walker BR, Solderberg S et al. Tissue-specificchanges in peripheral cortisol metabolism in obese women: increased adipose 11betahydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 330-3336.
55. Tomlison JW, Stewart PM. The functional consequences of 11betahydroxysteroid dehydrogenase expression in adipose tissue. Horm Metab Res 2002; 34: 746-751. (Pubitemid 36398718)
56. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170. (Pubitemid 33150673)
57. Morton NM, Seckl Jr. 11b-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008; 36: 146-164.
58. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91. (Pubitemid 23036092)
59. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 349: 1210-1213. (Pubitemid 27190044)
60. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376. (Pubitemid 32299662)
61. Kreitschmann-Andermahr I, Suarez P, Jennings R et al.GH/IGF-1 regulation in obesity - mechanisms and practical consequences in children and adults. Horm Res Paediatr. 2010; 73: 153-160.
62. Saukkonen T, Amin R, Williams RM et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 4634-4641. (Pubitemid 39244481)